October 11th 2024
A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.
September 27th 2024
September 27th 2024
Study Finds Hispanic, Latino Populations Underuse Cardiovascular Medication
August 5th 2020Among Hispanic and Latino patients with peripheral artery disease 31% reported use of antiplatelet therapy, 26% reported use of lipid-lowering therapy, and 57% reported use of antihypertensive therapy in a new study.
Single Question Improves Mortality Estimates in Elderly Atherosclerosis Patients
June 9th 2020When asked to elderly patients undergoing coronary artery calcium (CAC) scans, the results of a single question offer providers a better understanding of the individual’s risk of death: "On a scale of 1 - 10, how much do you exercise (0-none, 10-always)?"
FDA Expands Use of Ticagrelor to Patients Without History of MI or Stroke
June 2nd 2020The oral antiplatelet drug Ticagrelor (Brilinta, Astra Zeneca), was approved this week by the US Food and Drug Administration (FDA) for use in patients with coronary artery disease (CAD) who are at high risk for a first heart attack or stroke.
Guideline-Recommended CAD Care Better with Medicare Advantage than Fee For Service
March 6th 2019Patients with Medicare Advantage are more likely to receive guideline-recommended care for coronary artery disease than patients with Medicare Fee for Service. But whether that translates into better outcomes remains unclear, a study shows.